Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q4 2016 (← Previous) (Next →)

Filing Date: Feb 10, 2017

Total Value ($000): $123,236 (100.0% shares, 0.0% debt)

Holdings (11)

— Paratek Pharmaceuticals 32.5%

Value ($000) $40,046 Shares 2,600,410 Est. Cost $34.18 Unrealized —

— Juno Therapeutics 18.8%

Value ($000) $23,176 Shares 1,229,512 Est. Cost $52.22 Unrealized —

— Egalet 17.9%

Value ($000) $22,108 Shares 2,889,926 Est. Cost $5.98 Unrealized —

— FibroGen 14.3%

Value ($000) $17,595 Shares 822,175 Est. Cost $27.34 Unrealized —

— Nabriva Therapeutics 5.5%

Value ($000) $6,830 Shares 1,145,890 Est. Cost $9.50 Unrealized —

— Cidara Therapeutics 4.2%

Value ($000) $5,149 Shares 495,050 Est. Cost $10.40 Unrealized —

— ESSA Pharma 3.0%

Value ($000) $3,716 Shares 1,696,969 Est. Cost $5.22 Unrealized —

— Pieris Pharmaceuticals 1.9%

Value ($000) $2,376 Shares 1,697,384 Est. Cost $1.83 Unrealized —

EDIT Editas Medicine 0.9%

Value ($000) $1,074 Shares 66,162 Est. Cost $26.29 Unrealized -42.3%

— Dicerna Pharmaceuticals 0.5%

Value ($000) $644 Shares 223,457 Est. Cost $16.47 Unrealized —

— CymaBay Therapeutics 0.4%

Value ($000) $522 Shares 301,477 Est. Cost $1.94 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Paratek Pharmaceuticals	2,600,410	$40,046	32.5%	$34.18	—	Common Stock	699374302
—	Juno Therapeutics	1,229,512	$23,176	18.8%	$52.22	—	Common Stock	48205A109
—	Egalet	2,889,926	$22,108	17.9%	$5.98	—	Common Stock	28226B104
—	FibroGen	822,175	$17,595	14.3%	$27.34	—	Common Stock	31572Q808
—	Nabriva Therapeutics	1,145,890	$6,830	5.5%	$9.50	—	Sponsored ADR	62957M104
—	Cidara Therapeutics	495,050	$5,149	4.2%	$10.40	—	Common Stock	171757107
—	ESSA Pharma	1,696,969	$3,716	3.0%	$5.22	—	Common Stock	29668H104
—	Pieris Pharmaceuticals	1,697,384	$2,376	1.9%	$1.83	—	Common Stock	720795103
EDIT	Editas Medicine	66,162	$1,074	0.9%	$26.29	-42.3%	Common Stock	28106W103
—	Dicerna Pharmaceuticals	223,457	$644	0.5%	$16.47	—	Common Stock	253031108
—	CymaBay Therapeutics	301,477	$522	0.4%	$1.94	—	Common Stock	23257D103